Eur Rev Med Pharmacol Sci 2018; 22 (21): 7205-7213

DOI: 10.26355/eurrev_201811_16254

MicroRNA-31 inhibits osteosarcoma cell proliferation, migration and invasion by targeting PIK3C2A

L.-M. Chao, W. Sun, H. Chen, B.-Y. Liu, P.-F. Li, D.-W. Zhao

Graduate School of Southern Medical University, Guangzhou, Guangdong, P.R. China. Dewei_Zhao@sohu.com


OBJECTIVE: To elucidate the role of microRNA-31 (miR-31) in osteosarcoma and the molecular mechanism of miR-31 in the proliferation, migration, and invasion of osteosarcoma.

PATIENTS AND METHODS: Real Time-quantitative Polymerase Chain Reaction (RT-qPCR) was used to examine the expression of microRNA-31 in human osteosarcoma tissues. Pearson’s chi-squared test was used to analyze the correlation between microRNA-31 and clinicopathological features. Proliferation, migration, invasion, and PI3K3C2A protein in treated osteosarcoma cells were detected by Cell Counting Kit-8 (CCK-8) assay, transwell assay without Matrigel, transwell assay with Matrigel, and Western blot analysis, respectively.

RESULTS: qRT-PCR showed that miR-31 was down-regulated in osteosarcoma tissues compared with paired para-tumor bone tissues. The lower level of miR-31 was closely associated with high-grade osteosarcoma, metastasis, and poor overall survival. CCK-8 and transwell assay showed that miR-31 inhibited osteosarcoma cells proliferation, migration, and invasion. According to luciferase assay, miR-31 inhibits osteosarcoma cell proliferation, migration, and invasion through inhibiting PIK3C2A. Reversely, overexpression of PIK3C2A inhibited partial effect of miR-31 on proliferation, migration, and invasion in vitro.

CONCLUSIONS: MiR-31 inhibits osteosarcoma cell proliferation, migration, and invasion by targeting PICK3C2A. MiR-31 can thus be used as a therapeutic target in osteosarcoma treatment.

Free PDF Download

To cite this article

L.-M. Chao, W. Sun, H. Chen, B.-Y. Liu, P.-F. Li, D.-W. Zhao
MicroRNA-31 inhibits osteosarcoma cell proliferation, migration and invasion by targeting PIK3C2A

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 21
Pages: 7205-7213
DOI: 10.26355/eurrev_201811_16254